Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma

Matteo Santoni, Daniel Y.C. Heng, Gaetano Aurilio, Andrea Iozzelli, Lucilla Servi, Andrea Fabiani, Massimo Giannini, Roberta Mazzucchelli, Alessia Cimadamore, Marina Scarpelli, Mohamed S. Zaghloul, Nicola Battelli, Rodolfo Montironi

Research output: Contribution to journalArticlepeer-review


Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.

Original languageEnglish
Pages (from-to)416-423
Number of pages8
JournalCurrent Drug Targets
Issue number4
Publication statusPublished - 2020


  • CAR-T cells
  • Immunocheckpoint inhibitors
  • Immunotherapy
  • Programmed-death-1
  • Radiation therapy
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this